Balyasny Asset Management LLC Viking Therapeutics, Inc. Transaction History
Balyasny Asset Management LLC
- $54.8 Billion
- Q1 2024
A detailed history of Balyasny Asset Management LLC transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Balyasny Asset Management LLC holds 108,595 shares of VKTX stock, worth $6.76 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
108,595
Previous 125,000
13.12%
Holding current value
$6.76 Million
Previous $2.33 Million
282.8%
% of portfolio
0.02%
Previous 0.0%
Shares
17 transactions
Others Institutions Holding VKTX
# of Institutions
425Shares Held
63.1MCall Options Held
7.39MPut Options Held
5.13M-
Black Rock Inc. New York, NY8.27MShares$515 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.79MShares$485 Million0.01% of portfolio
-
Avoro Capital Advisors LLC New York, NY3.59MShares$224 Million3.55% of portfolio
-
State Street Corp Boston, MA3.33MShares$207 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA2.33MShares$145 Million0.02% of portfolio
About Viking Therapeutics, Inc.
- Ticker VKTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,688,496
- Market Cap $4.77B
- Description
- Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...